DUBLIN – Spybiotech Ltd. has secured a first vaccine deal for its proprietary Spytag/Spycatcher protein conjugation technology. The Serum Institute of India Pvt. Co. Ltd. (SIIPL) is employing the technology in a COVID-19 virus-like-particle (VLP)-based vaccine, which recently entered a phase I/II trial in Australia. An initial data readout is expected in October or November.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 54gene, Ascyrus Medical, Cryolife, Ehave, Feinstein Institute, Illumina, Infosys, Kaleidoscope Innovation, Novacyt, Ocular Therapeutix, Organovo, Orthopaedic Innovation Centre, Precipio, T2 Biosystems.
LONDON – Results from two non-randomized phase I/II trials of the Russian COVID-19 vaccine Sputnik V that recently received conditional regulatory approval show both a frozen and a freeze-dried formulation of the two-shot vaccine had a good safety profile and induced antibody responses in all 76 participants within 21 days.
RSS
